Johnson Winter & Slattery has advised Alceon Private Equity on its investment in Specialist Medical Services (SMS).
Alceon Private Equity is a leading private equity firm. Established in 2010, Alceon has invested over $3.8 billion of capital for its high net worth, family office and institutional clients across real estate, private equity and listed equity.
With this deal, the firm will make a move into ophthalmology and short stay medical services by investing in SMS, which is a roll-up of ophthalmology clinics and short stay hospitals in Australia. The business was founded by Carl Adams, who previously led the creation of radiology business QScan for Quadrant Private Equity.
The Johnson Winter & Slattery team was led by Partner Andrew Williams and Special Counsel Aidan Douglas, supported by Associates Katherine McNamara and Rebecca Proudman. Partner David Beckett and Special Counsel Man Loi advised on the Banking aspects of this transaction, Partner Christine Ecob, Senior Associate Stanley Yu and Associate Rachel Cox advised on the IP/IT aspects, Partner Peter Trevaskis and Associate Lucy Wang advised on the Property aspects.
“This investment by Alceon will enable SMS to capitalise on opportunities within short stay hospitals and ophthalmology clinics, which is a relatively untapped opportunity in the market. We are delighted to have supported Alceon in this strategic transaction, which is its third investment so far this year.”
Gilbert + Tobin advised SMS and Allens advised NAB.
About Johnson Winter & Slattery
Johnson Winter & Slattery is an independent national Australian law firm with over 65 partners and offices across Australia. We advise major Australian and international corporations and investment funds on their most challenging transactions and disputes across Australia and surrounding regions. Working closely with clients, knowing their business, and appreciating their commercial objectives, we tailor our approach to deliver cost-effective commercial outcomes.
Daya Knapton, Communications Manager
T: +61 2 8247 9638
Be the first to receive the latest articles, news and publications.